Is It Time to Test the Antiseizure Potential of Palmitoylethanolamide in Human Studies? A Systematic Review of Preclinical Evidence
ReviewOther animals
- Design
- Review
- Subjects
- Systematic review of animal studies; no human study found
- Dose used in the study
- Varied, in animal models
- Duration
- Not applicable
- What was measured
- Seizure frequency and severity in animal models of epilepsy and acute seizures; endocannabinoid changes; mechanisms
What the authors reported
In animal models, supplementation reduced seizure frequency and severity, in some cases comparably to antiseizure drugs, with pretreatment more effective. No human study exists.
Limits of this study
Preclinical only. The title asks whether human trials should begin; none has reported. One author consults for GW Pharma outside this work.
Source
PubMed 35053844 · doi:10.3390/brainsci12010101
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.